Physician profile
Melissa E Stembridge
NPI 1487913646
$123,289.87
in general payments reported to CMS, 2019-2025
7 companies · $8,930 in 2025
The $8,930 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47K · 2022: $330 · 2023: $45K · 2024: $21K · 2025: $8,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Travel and Lodging: $4,924 · Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,646.47 |
| Travel and Lodging | $4,923.91 |
| Food and Beverage | $250.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $123,040.77 | 2021-2025 | Omnipod, Omnipod |
| Novo Nordisk INC | $113.12 | 2022-2025 | Wegovy |
| Acella Pharmaceuticals, LLC | $36.23 | 2024 | NP Thyroid 60 |
| Lilly USA, LLC | $31.38 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $29.60 | 2022-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.15 | 2025 | Caplyta |
| Abbott Laboratories | $16.62 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Stembridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.